Antibiotic resistance breakers: Can repurposed drugs fill the antibiotic discovery void?

Nature Reviews Drug Discovery

Volumn 14, Issue 12, 2015, Pages 821-832

  Brown, David ^a  

^a Alchemy Biomedical Consulting   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BERBERINE; CEFACLOR; CEFIXIME; CEFODIZIME; CEFOTAXIME; CEFTOLOZANE PLUS TAZOBACTAM; CICLOPIROX; CLAVULANIC ACID; CURCUMIN; DICLOFENAC; EPIGALLOCATECHIN GALLATE; ERAVACYCLINE; IBUPROFEN; IVERMECTIN; LAURIC ACID; LOPERAMIDE; MACROLIDE; METRONIDAZOLE; NALOXONE; NALTREXONE; PLAZOMICIN; TAZOBACTAM; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DRUG APPROVAL; DRUG INDICATION; DRUG MARKETING; DRUG POTENTIATION; DRUG REPOSITIONING; ENTEROBACTER; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE INFECTION; HOST RESISTANCE; HUMAN; INFLAMMATION; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE; NEMATODIASIS; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; BACTERIUM; DRUG CONTROL; DRUG EFFECTS; PATHOGENICITY; PROCEDURES; TRENDS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIA; DRUG AND NARCOTIC CONTROL; DRUG REPOSITIONING; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 84948709890     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4675     Document Type: Review

References (152)

1. Rice, L. B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197, 1079-1081 (2008
2. Woodford, N., Wareham, D. W., Guerra, B.,&Teale, C. Carbapenemase-producing Enterobacteriaceae and non-Enterobacteriaceae from animals and the environment: an emerging public health risk of our own making?. J. Antimicrob. Chemother. 69, 287-291 (2014
3. Davis, S. C. Infections and the rise of antimicrobial resistance. UK Government [online], https://www.gov. uk/government/uploads/system/uploads/attachment- data/file/138331/CMO-Annual-Report- Volume-2-2011.pdf (2015
4. Centers for Disease Contol and Prevention. Antibiotic resistance threats in the United States, 2013. CDC [online], http://www.cdc.gov/drugresistance/pdf/ar-Threats-2013-508.pdf (2013
5. Bassetti, M.,&Righi, E. Eravacycline for the treatment of intra-Abdominal infections. Expert Opin. Investigat. Drugs 23, 1575-1584 (2014
6. Walkty, A., et al. In vitro activity of plazomicin against 5015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob. Agents Chemother. 58, 2554-2563 (2014
7. Zhanel, G G., et al. Ceftazidime-Avibactam: a novel cephalosporin/β-lactamase inhibitor combination Drugs.73, 159-177 (2013
8. Zhanel, G. G., et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs.74, 31-51(2014
9. White, A. R., et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-Acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53 (Suppl. 1), i3-i20 (2004
10. Prabhudesai, P. P., et al. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-Acquired pneumonia in adults. J. Indian Med. Assoc. 109, 124-127 (2011
11. Coates, A.,&Hu, Y. in Novel Antimicrobial Agents and Strategies Ch. 2 (eds Phoenix, D. A., Harris, F.,&Dennison, S. R.) (Wiley, 2014
12. Blair, J. M., Richmond, G. E.,&Piddock, L. J. Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol. 9, 1165-1177 (2014
13. Amsden, G. W. Anti-inflammatory effects of macrolides - an under-Appreciated benefit in the treatment of community-Acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J. Antimicrob. Chemother. 55, 10-21 (2005
14. Kudoh, S., et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low dose erythromycin. Amer. J. Resp. Crit. Care Med. 157, 1829-1832 (1998
15. Kudoh, S., et al. Clinical effects of low-dose long-Term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25, 632-642 (in Japanese) (1987
16. Tateda, K., et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45, 1930-1933 (2001
17. Molinari, G., et al. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 31, 681-688 (1993
18. Nguyen, T., et al. Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Curr. Opin. Pulmonary Med. 8, 521-528 (2002
19. Karabay, O., et al A new effect of acetylsalicylic acid?. Significantly lower prevalence of nasal carriage of Staphylococcus aureus among patients receiving orally administered acetylsalicylic acid. Infect. Control Hosp. Epidemiol. 27, 318-319 (2006)
20. Sedlacek, M., et al. Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. Am. J. Kidney Dis. 49, 401-408 (2007
21. Mazumdar, K., et al. Diclofenac in the management of E. coli urinary tract infections. In Vivo 20, 613-619 (2006
22. Mazumdar, K., et al. The anti-inflammatory non-Antibiotic helper compound diclofenac: an antibacterial drug target. Eur. J. Clin. Microbiol. Infect. Dis. 28, 881-891 (2009
23. Pongkorpsakol, P., et al. Inhibition of cAMP-Activated intestinal chloride secretion by diclofenac: cellular mechanism and potential application in cholera. PLoS Negl. Trop. Dis. 8, e3119 (2014
24. Vilaplana, C., et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208, 199-202 (2013
25. Eisen, D. P., et al. Low-dose aspirin and ibuprofen sterilizing effects on Mycobacterium tuberculosis suggest safe new adjuvant therapies for tuberculosis. J. Infect. Diseases 208, 1925-1927 (2013
26. Cicerale, S., Lucas, L. J.,&Keast, R. S. Antimicrobial, antioxidant and anti-inflammatory phenolic activities in extra virgin olive oil. Curr. Opin. Biotechnol. 23, 129-135 (2012
27. Pettengill, M., et al. Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells. PLoS ONE 7, e48456 (2012
28. Zhang, X., et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm. Res. 57, 524-529 (2008
29. Schlievert, P. M., et al. Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob. Agents Chemother. 36, 626-631 (1992
30. Projan, S. J., et al. Glycerol monolaurate inhibits the production of β-lactamase, toxic shock syndrome toxin 1, and other staphylococcal exoproteins by interfering with signal transduction. J. Bacteriol. 176, 4204-4209 (1994
31. Zhao, X., et al. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, 497-504 (2008
32. Tsoyi, K., et al. Metformin inhibits HMGB1 release in LPS-Treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br. J. Pharmacol. 162, 1498-1508 (2010
33. Rogers, A. C., et al. Activation of AMPK inhibits cholera toxin stimulated chloride secretion in human and murine intestine. PLoS ONE 8, e69050 (2013
34. Yuk, J. M., et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 6, 231-234 (2009
35. Montoya, D., et al. IL 32 is a molecular marker of a host defense network in human tuberculosis. Sci. Transl. Med. 20, 250 (2014
36. Dittmar, W., et al. Microbiological laboratory studies with ciclopiroxolamine. Drug Res. 31, 1317-1322 (1981
37. Carlson-Banning, K. M., et al. Toward repurposing Ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PLoS ONE 8, e69646 (2013
38. Niewerth, M., et al. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob. Agents Chemother. 47, 1805-1817 (2003
39. Dihazi, G. H., et al. Impact of the antiproliferative agent ciclopirox olamine treatment on stem cells proteome. World J. Stem Cells 5, 9-25 (2013
40. Zhou, H., et al. Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway. Oncotarget 5, 10140-10150 (2014
41. Weir, S. J., et al. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. J. Clin. Pharm. Ther. 36, 128-134 (2011
42. Eberhard, Y., et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114, 3064-3073 (2009
43. Kellner, H. M., et al. Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration. Arzneimittelforschung 31, 1337-1353 (in German) (1981
44. Minden, M. D., et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. Am. J. Hematol. 89, 363-368 (2014
45. Ejim, L., et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348-350 (2011
46. Taylor. P. L., et al A forward chemical screen identifies antibiotic adjuvants in Escherichia coli. ACS Chem. Biol. 7, 1547-1555 (2012
47. Tascini, C., et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 57, 3990-3993 (2013
48. Yu, H. H., et al. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J. Med. Food 8, 454-461 (2005
49. Kim, S. H., et al. Inhibition of the bacterial surface protein anchoring transpeptidase sortase by isoquinoline alkaloids. Biosci. Biotechnol. Biochem. 68, 421-424 (2004
50. Domadia, P. N. Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry 47, 3225-3234 (2008
51. Chu, M., et al. Role of berberine in anti-bacterial as a high-Affinity LPS antagonist binding to TLR4/MD 2 receptor. BMC Complement. Altern. Med. 14, 89 (2014
52. Jin, J. L., et al. Antibacterial mechanisms of berberine and reasons for little resistance of bacteria. Chinese Herbal Med. 3, 27-35 (2010
53. Li, H. M., et al. Berberine protects against lipopolysaccharide-induced intestinal injury in mice via α 2 adrenoceptor-independent mechanisms. Acta Pharmacol. Sin. 32, 1364-1372 (2011
54. Jeong, H. W., et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 296, 955-964 (2009
55. Zhang, M.,&Chen, L. Berberine in type 2 diabetes therapy: a new perspective for an old antidiarrheal drug?. Acta Pharmaceutica Sinica B 2, 379-386 (2012
56. Zhang, H., et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59, 285-292 (2009
57. Yin, J., Xing, H.,&Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57, 712-717 (2008
58. Fürst, R.,&Zündorf, I. Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediators Inflamm. 2014, 146832 (2014
59. Gupta, S. C., Patchva, S.,&Aggarwal, B. B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 15, 195-218 (2013
60. Moghadamtousi, S. Z., et al A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed. Res. Int. 186864 (2014
61. Mahady, G. B., et al. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res. 22 4179-4181 (2002
62. De, R., et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob. Agents Chemother. 53, 1592-1597 (2009
63. Aljamal, A. Effect of turmeric in peptic ulcer and H pylori. Plant Sci. Res. 3, 25-28 (2011
64. Di Mario, F., et al A curcumin-based 1 week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure?. Helicobacter 12, 238-243 (2007
65. Koosirirat, C., et al. Investigation of the antiinflammatory effect of Curcuma longa in Helicobacter pylori-infected patients. Int. Immunopharmacol. 10, 815-818 (2010
66. Patel, R.,&Yang, N. Inhibiting hospital associated infection of toxigenic Clostridium difficile using natural spice-Turmeric (curcumin). Amer. J. Gastroenterol. 105, S122-S122 (2010
67. Sasidharan, N. K., et al. In vitro synergistic effect of curcumin in combination with third generation cephalosporins against bacteria associated with infectious diarrhea. Biomed. Res. Int. 2014, 561456 (2014
68. Moghaddam, K. M., et al. The combination effect of curcumin with different antibiotics against Staphylococcus aureus. Int. J. Green Pharm. 3, 141-143 (2009
69. Mun, S. H., et al. Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytotherapy Research 19, 599-604 (2013
70. Park, B. S., et al. Curcuma longa L. constituents inhibit sortase A and Staphylococcus aureus cell adhesion to fibronectin. J. Agr. Food Chem. 53, 9005-9009 (2005
71. Aoki, H., et al. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol. Pharmacol. 72, 29-39 (2007
72. Gradisar, H., et al. MD 2 as the target of curcumin in the inhibition of response to LPS. J. Leukocyte Biol. 82, 968-974 (2007
73. Tu, X. K., et al. Curcumin inhibits TLR2/4 NF ?B signaling pathway and attenuates brain damage in permanent focal cerebral ischemia in rats. Inflammation 37, 1544-1551 (2014
74. Shuto, T., et al. Curcumin decreases toll-like receptor 2 gene expression and function in human monocytes and neutrophils. Biochem. Biophys. Res. Commun. 398, 647-652 (2010
75. Tu, C. T., et al. Curcumin attenuates concanavalin A induced liver injury in mice by inhibition of Toll-like receptor (TLR) 2, TLR4 and TLR9 expression. Intnl Immunopharmacol. 12, 151-157 (2012
76. Chan, M. M. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem. Pharmacol. 49, 1551-1556 (1995
77. Chainani Wu, N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J. Altern. Compl. Med. 9, 161-168 (2003
78. Bengmark, S. Curcumin, an atoxic antioxidant and natural NF?B, cyclooxygenase 2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. J. Parenteral Enteral Nutr. 30, 45-51 (2006
79. Jain, S. K., et al. Curcumin supplementation lowers TNF-α, IL 6, IL 8, and MCP 1 secretion in high glucose-Treated cultured monocytes and blood levels of TNF-α, IL 6, MCP 1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid. Redox Signal. 11, 241-249 (2009
80. Hansen, E., et al A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. J. Alzheimers Disease 19, 451-464 (2010
81. Ryan, A., et al A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog. 7, e1002076 (2011
82. Pothoulakis, C. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann. NY Acad. Sci. 915, 347-356 (2000
83. Sintara, K., et al. Curcumin suppresses gastric NF ?B activation and macromolecular leakage in Helicobacter pylori-infected rats. World J. Gastroenterol. 16, 4039-4046 (2010
84. Brennan, P.,&ONeill, L. A. Inhibition of nuclear factor ?B by direct modification in whole cells - mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem. Pharmacol. 55, 965-973 (1998
85. Steiner, T. S., et al. Faecal lactoferrin, interleukin 1b, and interleukin 8 are elevated in patients with severe Clostridium difficile colitis. Clin. Diagn. Lab. Immunol. 4, 719-722 (1997
86. Jafari, N. V., et al. Clostridium difficile modulates host innate immunity via toxin-independent and dependent mechanism(s). PLoS ONE 8, e69846 (2013
87. Rao, K., et al. The systemic inflammatory response to Clostridium difficile infection. PLoS ONE 9, e92578 (2014
88. Feghaly, R., et al. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin. Infect. Dis. 56, 1713-1721 (2013
89. Basu, P. P., et al. Turmeric enema: a novel therapy for C. difficile colitis (CDAD): A randomized, double blinded, placebo controlled prospective clinical trial. Internat. J. Infectious Diseases 15 (Suppl. 15), S39 (2011
90. Sharma, R. A., et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7, 1894-1900 (2001
91. Lim, G. P., et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377 (2001
92. Begum, A. N., et al. Curcumin structure function, bioavailability, and efficacy in models of neuroinflammation and Alzheimers disease. J. Pharmacol. Exp. Ther. 326, 196-208 (2008
93. Yang, F., et al. Curcumin inhibits formation of amyloid-β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005
94. McNaught, J. On the action of cold or lukewarm tea on Bacillus typhosus. J. R. Army Med. Corps 7, 372-373 (1906
95. Steinmann, J., et al. Anti-infective properties of epigallocatechin 3 gallate (EGCG), a component of green tea. Br. J. Pharmacol. 168, 1059-1073 (2013
96. Wolska, K. I., Grzes, K.,&Kurek, A. Synergy between novel antimicrobials and conventional antibiotics or bacteriocins. Pol. J. Microbiol. 61, 95-104 (2012
97. Yam, T. S., Hamilton-Miller, J. M.,&Shah S. The effect of a component of tea (Camellia sinensis) on methicillin resistance, PBP2? synthesis, and β-lactamase production in Staphylococcus aureus. J. Antimicrob. Chemother. 42, 211-216 (1998
98. Stapleton, P. D., et al. Modulation of β lactam resistance in Staphylococcus aureus by catechins and gallates. Int. J. Antimicrob. Agents 23, 462-467 (2004
99. Zhao, W., et al. Mechanism of synergy between epigallocatechin gallate and β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 1737-1742 (2001
100. Hu, Z. Q., et al. Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 48, 361-364 (2001
101. Hu, Z. Q., et al. Epigallocatechin gallate synergistically enhances the activity of carbapenems against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 558-560 (2002
102. Navarro-Martinez, M. D., et al. Antifolate activity of epigallocatechin gallate against Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 49, 2914-2920 (2005
103. Lee, H. C., et al. Effect of tea phenolics and their aromatic fecal bacterial metabolites on intestinal microbiota. Res. Microbiol. 157, 876-884 (2006
104. Reygaert, W.,&Jusufi, I. Green tea as an effective antimicrobial for urinary tract infections caused by Escherichia coli. Front. Microbiol. 4, 162 (2013
105. Li, W., et al A Major Ingredient of Green Tea Rescues Mice from Lethal Sepsis Partly by Inhibiting HMGB1. PLoS ONE 2, e1153 (2007
106. Zhao, W. H., et al. Inhibition of penicillinase by epigallocatechin gallate resulting in restoration of antibacterial activity of penicillin against penicillinase-producing Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 2266-2268 (2002
107. Stapleton, P. D., et al. The β-lactam-resistance modifier (-)-epicatechin gallate alters the architecture of the cell wall of Staphylococcus aureus. Microbiology 153, 2093-2103 (2007
108. Grandišar, H., et al. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J. Med. Chem. 50, 264-271 (2007
109. Zhang, Y. M.,&Rock, C. O. Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-Acid synthesis. J. Biol. Chem. 279, 30994-31001 (2004
110. Lee, K. M., et al. Protective mechanism of epigallocatechin 3 gallate against Helicobacter pylori-induced gastric epithelial cytotoxicity via the blockage of TLR 4 signaling. Helicobacter 9, 632-642 (2004
111. Zhao, W. H., et al. Inhibition by epigallocatechin gallate (EGCG) of conjugative R plasmid transfer in Escherichia coli. J. Infect. Chemother. 7, 195-197 (2001
112. Sudano Roccaro, A., et al. Epigallocatechin-gallate enhances the activity of tetracycline in staphylococci by inhibiting its efflux from bacterial cells. Antimicrob. Agents Chemother. 48, 1968-1973 (2004
113. Li, W., et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem. Pharmacol. 81, 1152-1163 (2011
114. Kim, H. S., et al. Epigallocatechin gallate (EGCG) stimulates autophagy in vascular endothelial cells: a potential role for reducing lipid accumulation. J. Biol. Chem. 288, 22693-22705 (2013
115. Zhou, J., et al. Epigallocatechin 3 gallate (EGCG), a green tea polyphenol, stimulates hepatic autophagy and lipid clearance. PLoS ONE 9, e87161 (2014
116. Ullmann, U., et al A single ascending dose study of epigallocatechin gallate in healthy volunteers. J. Int. Med. Res. 31, 88-101 (2003
117. Lambert, J. D., et al. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin 3 gallate. Drug Metab. Dispos. 34, 2111-2116 (2006
118. Matsumoto, Y., et al. Antibacterial and antifungal activities of new acylated derivatives of epigallocatechin gallate. Front. Microbiol. 3, 53 (2012
119. Hutchinson, M. R., et al. Evidence that opioids may have toll like receptor 4 and MD 2 effects. Brain Behav. Immun. 24, 83-95 (2010
120. Hutchinson, M. R., et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J. Neurosci. 32, 11187-11200 (2012
121. Dawson, A. in Medical Toxicology 3rd edn (ed. Dart, R.) 228-230 (Lippincott, Williams and Wilkins, 2004
122. Clifton, L. A., et al. Effect of divalent cation removal on the structure of Gram-negative bacterial outer membrane models. Langmuir 31, 404-412 (2015
123. Gill, E. E., Franco, O. L.,&Hancock, R. E. Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. Chem. Biol. Drug Des. 85, 56-78 (2015
124. Chauhan, A., et al. Full and broad-spectrum in vivo eradication of catheter-Associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob. Agents Chemother. 56, 6310-6318 (2012
125. Deretic, V. Autophagy in immunity and cell-Autonomous defense against intracellular microbes. Immunol. Rev. 240, 92-104 (2011
126. Campoy, E.,&Colombo, M. I. Autophagy in intracellular bacterial infection. Biochim. Biophys. Acta 1793, 1465-1477 (2009
127. Nakagawa, I., et al. Autophagy defends cells against invading group A Streptococcus. Science 306, 1037-1040 (2004
128. Birmingham, C. L., et al. Autophagy controls salmonella infection in response to damage to the salmonella-containing vacuole. J. Biol. Chem. 281, 11374-11383 (2006
129. Ogawa, M., et al. Escape of intracellular Shigella from autophagy. Science 307, 727-731 (2005
130. Yano, T., et al. Autophagic control of Listeria through intracellular innate immune recognition in drosophila. Nat. Immunol. 9, 908-916 (2008
131. Gutierrez, M. G., et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119, 753-766 (2004
132. Amano, A., Nakagawa, I.,&Yoshimori, T. Autophagy in innate immunity against intracellular bacteria. J. Biochem. 140, 161-166 (2006
133. Vergne, I., et al. Autophagy in immune defense against Mycobacterium tuberculosis. Autophagy 2, 175-178 (2006
134. Mostowy, S. Autophagy and bacterial clearance: a not so clear picture. Cell. Microbiol. 15, 395-402 (2013
135. Kuballa, P., et al. Autophagy and the immune system. Annu. Rev. Immunol. 30, 611-646 (2012
136. Levine, B., Mizushima, N.,&Virgin, H. W. Autophagy in immunity and inflammation. Nature 469, 323-335 (2011
137. Poels, J., et al. Expanding roles for AMP-Activated protein kinase in neuronal survival and autophagy. Bioessays 31, 944-952 (2009
138. Inoki, K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126, 955-968 (2006
139. Ulgherait, M., et al. AMPK modulates tissue and organismal aging in a non-cell-Autonomous manner. Cell Rep. 8, 1767-1780 (2014
140. Wang, W. H., et al. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 52, 490-495 (2003
141. Price, C. T., et al. The effects of salicylate on bacteria. Internat. J. Biochem. Cell Biol. 32, 1029-1043 (2000
142. Nicolau, D. P., et al. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 39, 1748-1751 (1995
143. Nicolau, D. P., et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect. Immun. 61, 1593-1595 (1993
144. Dutta, N. K., et al. The anti-inflammatory drug diclofenac retains anti-listerial activity in vivo. Lett. Appl. Microbiol. 47, 106-111 (2008
145. Dutta, N. K., et al. Potential management of resistant microbial infections with a novel non-Antibiotic: the anti-inflammatory drug diclofenac sodium. Int. J. Antimicrob. Agents 30, 242-249 (2007
146. Dutta, N. K., et al. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int. J. Antimicrob. Agents 30, 336-340 (2007
147. Zhang, X., et al. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. Int. Immunopharmacol. 9, 354-359 (2009
148. Bae, H. B., et al. AMP-Activated protein kinase enhances the phagocytic ability of macrophages and neutrophils. FASEB J. 25, 4358-4368 (2011
149. Singhal, A., et al. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 6, 263ra159 (2014
150. Maeurer, M.,&Zumla, A. The host battles drug-resistant tuberculosis. Sci. Transl. Med. 6, 263fs47 (2014
151. Salahuddin, N., et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis] A randomized, placebo-controlled clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. BMC Infect. Dis. 13, 22 (2013
152. Anand, P. K.,&Kaul, D. Vitamin D3 dependent pathway regulates TACO gene transcription. Biochem. Biophys. Res. Commun. 310, 876-877 (2003